Recent Updates
Recently added Catalysts

Roche Holding AG

RHHBY
Biotech · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$57.43
▲ · %

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Quarterly Cash
Unlock full RHHBY financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
1.03 M
Value Traded
58.94 M
Short % Float
-

Cash Data

Unlock RHHBY cash position
  • Cash FlowProfitable
  • SEC Filing

Key Stats

Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every RHHBY catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RHHBY Catalyst Timeline

Dated clinical, regulatory and corporate events for Roche Holding AG

Unlock the full RHHBY catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RHHBY actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-11Alecensa (alectinib hydrochloride) PDUFA Date ApprovedPDUFA
Unlock 14 more RHHBY historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

B78 / 100
Pipeline Score
$9.9B
Pipeline Value
Not rated
Valuation Signal
153
Drugs Scored
-
rNPV / MCap
Top 3%
Large Pharma
(rank 21 of 655)
Percentile Rank
Roche Holding AG holds a solid B-grade pipeline (78/100), with $49.4B risk-adjusted pipeline value, led by Ro 205-2349 in Diabetes (Phase 2).
Showing 1 of 153 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Ro 205-2349 Small moleculeCompletedNCT00057317DiabetesPhase 2 COMPLETED 190Dec 1, 2003
Unlock the RHHBY pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RHHBY program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Example Drug Example indication for clinical evaluationPhase 32025-12-01The study met its primary endpoint demonstrating statistically significant improvement.Read MorePhase 3 Study Results AnnouncementRead More
Scroll for more · summaries link to the source press release
Unlock every RHHBY trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RHHBY insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full RHHBY insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in RHHBY

Fund % of Portfolio Current MV Shares Owned Activity
Sofinnova Investments, Inc. 4.1 % 70.76 M 1.37 M
Unlock every fund holding RHHBY
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RHHBY
Shares held by hedge funds each quarter, and who bought or sold.

RHHBY Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock RHHBY option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RHHBY option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RHHBY options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RHHBY ranks across every disease it competes in

Competitive Position is a premium feature
See how RHHBY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RHHBY News

About Roche Holding AG

BIOPHARMAWATCH ELITE PLUS
Trade the next RHHBY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime